| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1911-10-26 |
| Identifiers | MRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692 |
| Document date | 1964-03-09 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Cardiac test results and the start of treatment. [S]
Ms. Jackson returns two weeks after the consultation with the results of her heart and eye tests. The Holter recorded first-degree atrioventricular block throughout, ectopic beats making up 6 percent of all beats, and three short runs of ventricular tachycardia, one during her palpitations. The echocardiogram and cardiac MRI show a mildly reduced pumping function (ejection fraction 47 percent) with scarring in the base of the septum and the side wall, and the FDG-PET three days ago shows active inflammation at the same sites. The eye examination was normal. Hepatitis B and C tests were negative, and she is not immune to hepatitis B. Cultures from the EBUS samples show no growth at three weeks. She is breathless on one flight of stairs, has had two more spells of palpitations, and has not fainted. She saw Dr. Asante-Miller and the cardiology team this morning. She asked whether she will sing again and was told that, with treatment, most people return to their work. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Holter | PR 230 to 250 ms; ventricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia up to 8 beats |
| Echocardiogram and MRI | Ejection fraction 47 percent; patchy enhancement of the basal anteroseptum and inferolateral wall |
| FDG-PET | Focal myocardial uptake matching the MRI; active hilar and mediastinal nodes |
| Eyes | No uveitis; normal pressures |
| Infection screening | Hepatitis B and C negative; not immune to hepatitis B; cultures no growth at three weeks |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or weight loss |
| Respiratory | Positive | Breathless on one flight of stairs; dry cough |
| Cardiovascular | Positive | Two more spells of palpitations; no fainting, chest pain or ankle swelling |
| Eyes | Negative | No redness or blurred vision |
| Endocrine | Negative | No thirst or frequent urination |
| Psychiatric | Positive | Frightened by the heart findings, steadied by her faith; PHQ-9 7; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning | 40 mg each morning | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays | 15 mg once weekly | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Folic acid 1 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food | 1500 mg once daily with food | Oral route | 1964-03-09 to 1964-07-06 | completed | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1964-03-09 | Body height | 170 | cm | S |
| 1964-03-09 | Body weight | 91.2 | kg | S |
| 1964-03-09 | Body mass index (BMI) [Ratio] | 31.6 | kg/m2 | S |
| 1964-03-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1964-03-09 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1964-03-09 | Heart rate | 80 | /min | S |
| 1964-03-09 | Respiratory rate | 18 | /min | S |
| 1964-03-09 | Body temperature | 36.6 | Cel | S |
| 1964-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1964-03-09 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-03-09 | Leukocytes [#/volume] in Blood by Automated count | 4.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-03-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 1964-03-09 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-03-09 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1964-03-09 | Calcium [Mass/volume] in Serum or Plasma | 10.6 | mg/dL | 8.6-10.3 mg/dL | High | S |
| 1964-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-35 U/L | Normal | S |
| 1964-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-35 U/L | Normal | S |
| 1964-03-09 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 124 | U/L | 35-104 U/L | High | S |
| 1964-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-03-09 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 240 | pg/mL | <=125 pg/mL | High | S |
| 1964-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |
Vital signs recorded on 1964-03-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 91.2 kg; blood pressure 124/78, pulse 80 with occasional ectopic beats |
| Respiratory | Clear to auscultation |
| Cardiovascular | Occasional ectopic beats; no murmur, gallop or ankle swelling; jugular venous pressure normal |
| Mouth | No thrush; teeth in good repair |
| Skin | No rash or plaques |
| Psychiatric | Thoughtful; asks about her voice and travel |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | active | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
| Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | D86.85 | S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R. |
| Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | Z79.52 | S — Synthetic treatment status. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Holter monitoring | When the ECG is abnormal or there are palpitations | Up to date | Ventricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia; first-degree block; no high-grade block |
| Imaging | Echocardiogram and cardiac MRI | When cardiac involvement is suspected | Up to date | Ejection fraction 47 percent; late gadolinium enhancement about 9 percent of left ventricular mass |
| Imaging | Cardiac FDG-PET | Before glucocorticoids, then three to six months into treatment | Up to date | Three days ago: active myocardial inflammation matching the MRI; repeat after about five months |
| Examination | Eye examination | At diagnosis, then yearly | Up to date | Five days ago: normal |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Ordered | Cultures no growth at three weeks; final at six to eight weeks |
| Laboratory | Methotrexate safety: blood count, liver tests and creatinine | Before starting; every two to four weeks for the first three months; then every eight to twelve weeks | Completed today | Baseline: hemoglobin 12.6 g/dL, white cells 4.8, lymphocytes 0.9, platelets 240; ALT 27, AST 29, alkaline phosphatase 124 U/L, albumin 4.0 g/dL; creatinine 1.02 mg/dL, eGFR 66 |
| Laboratory | Hepatitis B and C screening | Before immunosuppressive treatment | Up to date | Negative; not immune to hepatitis B, so vaccination starts today |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 10.6 mg/dL |
| Laboratory | Glucose before glucocorticoids | At the start, then at each visit | Completed today | Glucose 101 mg/dL; A1c 5.9% at the first visit |
| Laboratory | NT-proBNP | At the cardiac diagnosis and when symptoms change | Completed today | 240 pg/mL |
| Imaging | Bone density (DXA) and FRAX | At the start of glucocorticoids expected to last three months or more | Ordered | Booked for next week |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with a second immunosuppressant | Completed today | Atovaquone started; trimethoprim-sulfamethoxazole avoided with methotrexate |
| Medication safety | Vaccination before immunosuppression | Before or as treatment starts | Completed today | PCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; influenza at the first visit; no live vaccines |
| Referral | Cardiology and electrophysiology | When cardiac sarcoidosis is diagnosed | Referred | Seen with Dr. Asante-Miller today; electrophysiology study booked for next week |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 7 |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before immunosuppression; Recombinant zoster vaccine, dose 1 of 2; Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 [S]
Guideline basis: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Bone density next week; electrophysiology study next week. No driving for a week after any device implant. Nine-week review with lung function and blood tests. Call 911 for fainting, a sustained racing heart or a defibrillator shock. Next scheduled visit 1964-05-11: nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule. [S]